SimBioSys®, an innovative TechBio company specialising in spatial biophysics and artificial intelligence (AI), has launched its second clinical application, TumorSight Plan. This application aims to transform surgical planning for the over 270,000 patients diagnosed annually with early-stage breast cancer in the United States.

Surgery is the primary treatment for most patients with early-stage breast cancer. However, surgeons often face challenges in making precise treatment decisions.

There is a notable uncertainty regarding the complete removal of a patient’s tumour and achieving optimal cosmetic outcomes, which can lead to a preference for mastectomy over breast-conserving surgery.

With TumorSight Plan, surgeons now have access to visualisation tools and data-driven insights that enhance provider-patient interactions and support tailored treatment planning.

This application is built on the FDA-cleared TumorSight Viz, a 3D visualisation solution that complements the growing use of MRI imaging in breast cancer treatment. Both TumorSight Plan and Viz are available to breast surgeons across the country and will be showcased at the American Association of Breast Surgeons conference in Orlando from April 11 to 13.

SimBioSys® is committed to expanding the TumorSight™ platform with plans to introduce additional innovative tools focused on surgical planning, risk assessment, treatment selection, and precision dosing. This comprehensive approach seeks to provide extensive support throughout the cancer care journey, highlighting the potential of true precision medicine.

Currently, treatment decisions for breast cancer can vary significantly based on the surgeon rather than the specific characteristics of the disease. By collaborating with leading surgeons across the United States, SimBioSys® aims to leverage AI to make surgical planning more scientific. TumorSight Plan offers a platform for breast cancer surgeons to engage in more analytical, patient-focused decision-making, which may increase the number of women eligible for breast-conserving surgery.




Source: simbiosys.com

Report Abuse